Celltrion's (KRX:068270) Steqeyma, or ustekinumab-stba, a biosimilar to Stelara (ustekinumab) was added to the Costco Member Prescription Program to improve access to costly inflammatory disease treatments.

Steqeyma is used to treat plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis in adults and select pediatric patients. The drug is available as a subcutaneous injection and intravenous infusion, Celltrion said last week.

Costco members, including self-funded employer plans and uninsured individuals, gained access to the biosimilar through Costco Specialty Pharmacies from April 1.

Shares of Celltrion rose more than 1% in recent trade on Thursday.